These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28250876)

  • 1. [Evaluation of early warning indicators of HIV resistance to antiretroviral (ARV) drugs in Ivory Coast in 2011].
    Yao KJ; Damey NF; Konan DJ; Aka J; Aka-Konan S; Ani A; Bonle MT; Kouassi D
    Pan Afr Med J; 2016; 25():52. PubMed ID: 28250876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire.
    Hanson DL; Adjé-Touré C; Talla-Nzussouo N; Eby P; Borget MY; Kouadio LY; Celestin BE; Tossou O; Eholie S; Kadio A; Chorba T; Nkengasong JN
    AIDS Res Hum Retroviruses; 2009 May; 25(5):489-95. PubMed ID: 19388820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV drug resistance early warning indicators in Namibia for public health action.
    Jonas A; Gweshe J; Siboleka M; Deklerk M; Gawanab M; Badi A; Sumbi V; Pereko D; Blom A; Mwinga S; Jordan MR; Jerger L; Lau K; Hong SY
    PLoS One; 2013; 8(6):e65653. PubMed ID: 23762406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When do HIV-infected persons start with antiretroviral therapy? A retrospective analysis of patients' monitoring and treatment status in general practice, as compared with the 1991 Dutch HIV treatment guidelines.
    Reedijk M; Wigersma L; Mohrs J
    Fam Pract; 1998 Dec; 15(6):525-8. PubMed ID: 10078791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [National profile of early warning indicators of HIV pharmaco-resistance in Cameroon].
    Billong SC; Fokam J; Penda CI; Mvilongo EA; Fodjo R; Messeh A; Anoubissie JD; Kegne C; Nguekam G; Batamack YA; Billong EJ; Moutapam PR; Ndjolo A; Bonono L; Elat JB; Bissek ACZ
    Pan Afr Med J; 2020; 37():374. PubMed ID: 33796187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire.
    Adjé-Touré C; Hanson DL; Talla-Nzussouo N; Borget MY; Kouadio LY; Tossou O; Fassinou P; Bissagnene E; Kadio A; Nolan ML; Nkengasong JN
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):911-7. PubMed ID: 18593341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring HIV drug resistance using early warning indicators in China: results from a pilot survey conducted in 2008.
    Ma Y; Zhang F; Li H; Wu H; Zhang J; Ding Y; Zhao D; Fang H; Zhou S; Liu Z; Zhang L; Osborne C; Seguy N; Zhao Y
    Clin Infect Dis; 2012 May; 54 Suppl 4():S300-2. PubMed ID: 22544191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-audit of antiretroviral prescribing in HIV patients.
    Hextall R; Monteiro EF
    Int J STD AIDS; 2001 Jun; 12(6):398-9. PubMed ID: 11368823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-antiretroviral drugs uses among HIV-infected persons receiving antiretroviral therapy in Senegal: Costs and factors associated with prescription].
    Diouf A; Youbong TJ; Maynart M; Ndoye M; Diéye FL; Ndiaye NA; Koita-Fall MB; Ndiaye B; Seydi M
    Rev Epidemiol Sante Publique; 2017 Aug; 65(4):295-300. PubMed ID: 28502580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of poor retention on antiretroviral therapy as a major HIV drug resistance early warning indicator in Cameroon: results from a nationwide systematic random sampling.
    Billong SC; Fokam J; Penda CI; Amadou S; Kob DS; Billong EJ; Colizzi V; Ndjolo A; Bisseck AZ; Elat JN
    BMC Infect Dis; 2016 Nov; 16(1):678. PubMed ID: 27846809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapeutic aspect of antibiotic therapy during acute community-acquired pneumonia in adults at the University Hospital of Cocody (Abidjan).
    Kouakou-Siransy G; Horo K; Effo E; Kamenan A; N'guessan-Irié G; Boko-Kouassi A; Aka-Anguy E; Die Kakou H
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):940-6. PubMed ID: 26413732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006.
    Toni Td; Masquelier B; Minga A; Anglaret X; Danel C; Coulibaly A; Chenal H; Dabis F; Salamon R; Fleury HJ;
    AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1155-60. PubMed ID: 17919113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008-2010: lessons and challenges for low-resource settings.
    Fokam J; Billong SC; Bissek AC; Kembou E; Milenge P; Abessouguie I; Nkwescheu AS; Tsomo Z; Aghokeng AF; Ngute GD; Ndumbe PM; Colizzi V; Elat JB
    BMC Public Health; 2013 Apr; 13():308. PubMed ID: 23565992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.
    Richard N; Juntilla M; Abraha A; Demers K; Paxinos E; Galovich J; Petropoulos C; Whalen CC; Kyeyune F; Atwine D; Kityo C; Mugyenyi P; Arts EJ
    AIDS Res Hum Retroviruses; 2004 Apr; 20(4):355-64. PubMed ID: 15157354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the follow-up of AIDS patients with ARV treatment at the Treichville sexually transmitted disease center of the National Institute of Public Hygiene (INHP), Abidjan, from 2009 to 2013.
    Desiré Zadi G; Djoman C; Djédjé DM; Tiembré I
    Med Sante Trop; 2018 Nov; 28(4):404-407. PubMed ID: 30799827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for the developing world.
    GMHC Treat Issues; 1997-1998 Winter; 12(1):32. PubMed ID: 11364989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Socio-economic and health characteristics of HIV-infected patients seeking care in relation to access to the Drug Access Initiative and to antiretroviral treatment in Côte d'Ivoire.
    Msellati P; Juillet-Amari A; Prudhomme J; Akribi HA; Coulibaly-Traore D; Souville M; Moatti JP;
    AIDS; 2003 Jul; 17 Suppl 3():S63-8. PubMed ID: 14565611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.